Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Prepaid clinical development costs Prepaid Clinical Development Costs, Current Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Principal amount of convertible notes Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Daiichi Sankyo Europe GmbH ("DSE") Daiichi Sankyo Europe Gmbh [Member] Member stands for the Daiichi Sankyo Europe GmbH ("DSE"). Exclusive Developmental Activities Exclusive Developmental Activities [Member] Represents information pertaining to exclusive developmental activities. Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Average trading-day period Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Number of consecutive trading days Number Of Consecutive Trading Days Number Of Consecutive Trading Days Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt fair value Debt Instrument, Fair Value Disclosure Milestone amount for worldwide sales to receive the third payment Milestone Amount for Worldwide Sales to Receive Third Payment Milestone amount for worldwide sales to receive the Third Payment. Pre Funded Warrant Pre Funded Warrant [Member] Pre Funded Warrant Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Range [Domain] Statistical Measurement [Domain] Depreciation expense Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Percentage of increase in royalty rate upon drawdown of third payment Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment The percentage of increase in the Royalty Rate upon drawdown of the Third Payment. Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Net loss Net loss Net Income (Loss) Attributable to Parent Net (Loss) Income Per Common Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Cumulative purchaser payment adjustment Revenue Interests Payment On Which Agreement Terminates Revenue Interests Payment On Which Agreement Terminates Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Total assets at fair value Assets, Fair Value Disclosure Aggregate Intrinsic Value Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract] Plan Name [Axis] Plan Name [Axis] Collaboration revenue Collaboration Revenue [Member] Represents the information pertaining to collaboration revenue. Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Unrecognized stock-based compensation expense, RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Milestone payments related to total net sales achievements Future Payment Milestone, Sales Milestones The total amount of potential future payments related to total net sales achievements for Otsuka in Japan. Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] ESPP Shares issuable related to the ESPP Employee Stock [Member] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Amount of subsequent installment, subject to regulatory approval Amount of Subsequent Installment, Subject to Regulatory Approval The amount of the subsequent installment which is subject to regulatory approval. Redemption amount Revenue Interest Payments, Redemption Value Revenue Interest Payments, Redemption Value Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current Consecutive number of months sales must be at or above milestone amount Consecutive Number of Months Sales Must Be At or Above Milestone Amount The consecutive number of months sales must be at or above the milestone amount. Summary of Activity Relating to the Company's RSUs Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Total amount of subsequent installment, subject to RIPA terms and conditions Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement. Consideration cash payment Future Up-Front Payment Future Up-Front Payment Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Stock compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock purchasable under warrants (in shares) Common Stock Purchasable Under Warrants Common Stock Purchasable Under Warrants Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Number of business days Number Of Business Days Number Of Business Days Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021 Revenue Interest Rate, Tier Two The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021. Weighted-Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of RSUs Number of PBRSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Debt instrument, convertible, threshold percentage of last reported sale price Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Outstanding and at the beginning of period (in dollars per share) Outstanding and unvested at the at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Convertible Notes Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024 Revenue Interest Rate, Tier Three The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024. Common stock purchasable under prefunded warrants (in shares) Common Stock Purchasable Under Prefunded Warrants Common Stock Purchasable Under Prefunded Warrants Purchase of capped call options associated with convertible notes Payments for Derivative Instrument, Financing Activities Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised. Milestone payment, first JNDA submissions Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory. Other Accrued Liabilities Other Liabilities Disclosure [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement Issuance costs to additional paid in capital Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total assets Assets Purchaser Discounts And Commissions And Offering Expenses Payable Purchaser Discounts And Commissions And Offering Expenses Payable [Member] Purchaser Discounts And Commissions And Offering Expenses Payable Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] PBRSUs Unvested PBRSUs Performance Shares [Member] Trade Receivables Trade Accounts Receivable [Member] Placement fees Payments for Repurchase of Private Placement Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Debt interest expense Interest Expense, Debt Study patients enrolled Number Of Study Patients Number Of Study Patients Accrued compensation Employee-related Liabilities, Current Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Other prepaid and current assets Prepaid Expense and Other Assets, Current Net Loss Per Common Share Earnings Per Share [Text Block] Liability from Sale of Future Revenues [Table] Liability from Sale of Future Revenues [Table] Disclosure of information about liabilities from the sale of future royalty revenues. Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Investments Short-Term Investments [Member] Equity Award [Domain] Award Type [Domain] Warrants issued for shares of common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Weighted-average period over which remaining unrecognized compensation cost will be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Registrant Name Entity Registrant Name Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Summary of Revenue Interest Liability Activity During the Period Schedule of Revenue Interest Liability [Table Text Block] Tabular disclosure of information pertaining to the revenue interest liability. Entity Address, City or Town Entity Address, City or Town Purchase discount Employee Stock Purchase Plan, Percentage Discount on Shares The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Operating expenses: Operating Expenses [Abstract] Percentage of revenue interest payments to qualify for third payment applicable percentage Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage Minimum Minimum [Member] Proceeds from warrant amendment Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised. Duration of offering periods Employee Stock Purchase Plan, Duration of Offering Period The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Unamortized debt discount and issuance costs Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Shares issuable upon conversion of convertible notes Convertible Debt Securities [Member] Weighted-Average Remaining Contractual Term (Years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Upfront cash payment received (paid) Up-Front Payment The amount of up-front payment received (paid) . Accrued interest on convertible notes Interest Payable, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Net Sales Threshold [Axis] Net Sales Threshold [Axis] Net Sales Threshold Use of Estimates Use of Estimates, Policy [Policy Text Block] Pre Funded Warrant And Accompanying Warrant Pre Funded Warrant And Accompanying Warrant [Member] Pre Funded Warrant And Accompanying Warrant Revenue interest liability Revenue Interest Liability, NonCurrent Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent. Accounts payable Increase (Decrease) in Accounts Payable Significant Accounting Policies [Table] Significant Accounting Policies [Table] Disclosure of information about significant accounting policies. Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Cardiovascular Risk Outcome Less than Twenty Percent Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent [Member] Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent Income Taxes Income Tax Disclosure [Text Block] Exchange Agreement, threshold trading days Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days Number of revenue sources Number Of Sources Of Revenue Number Of Sources Of Revenue Remaining redemption amount Revenue Interest Payments, Remaining Redemption Value Revenue Interest Payments, Remaining Redemption Value Finished goods Inventory, Finished Goods, Net of Reserves Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Daiichi Sankyo Co. Ltd Daiichi Sankyo Co. Ltd [Member] Daiichi Sankyo Co. Ltd Inventories Inventory, Policy [Policy Text Block] Cash payment to the Company upon first commercial sales in the DSE Territory Cash Payment to be Received upon First Commercial Sales The amount of cash payment to the Company upon first commercial sales in the DSE Territory. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Cardiovascular Risk Outcome Greater than Twenty Percent Cardiovascular Risk Outcome Greater Than Twenty Percent [Member] Cardiovascular Risk Outcome Greater Than Twenty Percent Treasury Stock Treasury Stock [Member] Total stockholders’ deficit Beginning balance Ending balance Stockholders' Equity Attributable to Parent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Transfer of assets between levels Fair Value Measurement Asset Transfers between Levels Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period. Potential additional future payments Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones. Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Issued stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Capitalized issuance costs Unamortized Transaction Costs on Revenue Interest Agreement Amount of transaction costs on revenue interest agreement. Type Of Risk[Axis] Type Of Risk [Axis] Type Of Risk Accumulated Deficit Retained Earnings [Member] Unrecognized stock-based compensation expense, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Summary of Warrants and Pre-funded Warrants Outstanding Summary Of Warrants And Pre Funded Warrants Outstanding [Table Text Block] Summary Of Warrants And Pre Funded Warrants Outstanding One time partial call One Time Partial Call One Time Partial Call Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Common Stock Common Stock [Member] Other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Prepayment of forward stock repurchase transaction Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] Revenue Recognition Revenue [Policy Text Block] Investments Marketable Securities, Policy [Policy Text Block] Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Summary of Activity Relating to the Company's PBRSU's Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Percentage of revenues interests payment on which agreement terminates, after third anniversary Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary Document Quarterly Report Document Quarterly Report Liability Related to the Revenue Interest Purchase Agreement Liability from Sale of Future Revenues [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Current assets: Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Otsuka Pharmaceutical Co, Ltd. Otsuka Pharmaceutical Co Ltd [Member] Represents information pertaining to Otsuka Pharmaceutical Co, Ltd. Statistical Measurement [Axis] Statistical Measurement [Axis] Underlying common stock (in shares) Treasury Stock, Shares, Acquired Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Collaborations with Third Parties Collaborations with Third Parties n/a RIPA Amendment To The Security Agreement And Waiver RIPA Amendment To The Security Agreement And Waiver [Member] RIPA Amendment To The Security Agreement And Waiver Accumulated deficit Retained Earnings (Accumulated Deficit) Convertible Senior Notes Due 2025 Convertible Senior Notes Due 2025 [Member] Convertible Senior Notes Due 2025 Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021 Net Sales Threshold To Include Worldwide Sales In Covered Territory Net Sales Threshold To Include Worldwide Sales In Covered Territory Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Recurring fair value measurement Fair Value, Recurring [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Percentage of risk reduction Percentage Of Risk Reduction Percentage Of Risk Reduction Revenue interest liability Revenue interest liability, beginning balance Revenue interest liability, ending balance Revenue Interest Liability Represents the current and non-current portion of the Revenue Interest Liability. Interest expense recognized Revenue Interest Liability, Increase for Interest Expense Recognized The amount of increase in the revenue interest liability attributable to interest expense recognized during the period. Document Fiscal Year Focus Document Fiscal Year Focus Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Outstanding at the beginning of period (in shares) Outstanding and unvested at the ending of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Other accrued liabilities Total other accrued liabilities Accrued Liabilities and Employee-related Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product sales, net Product [Member] Right of use operating lease assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Trailing number of months sales must be at or above milestone amount Trailing Number Of Months Sales Must Be At Or Above Milestone Amount The trailing number of months sales must be at or above the milestone amount. Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Reconciliation of Cash and Cash Equivalents and Restricted Cash Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Tabular disclosure of reconciliation of cash and cash equivalents and restricted cash presented on the Condensed Balance Sheets to the same amounts presented on the Condensed Statements of Cash Flows. Document Transition Report Document Transition Report Local Phone Number Local Phone Number Exchange Agreement, amount of principal amount converted into common stock Debt Conversion, Converted Instrument, Amount Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recently Implemented Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of goods sold Other Cost and Expense, Operating Common stock being exchanged (in shares) Debt Conversion, Converted Instrument, Shares Issued Prepaids and other assets Increase (Decrease) in Prepaid Expense and Other Assets Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Number of major customers Concentration Risk, Number of Major Customers The number of the Company's major customers. Treasury stock (in shares) Treasury Stock, Shares Revenue interest liability Revenue Interest Liability, Current Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current. Hypothetical repayment obligation Hypothetical Repayment Obligation Based On Sales Generated Hypothetical Repayment Obligation Based On Sales Generated Provision for income taxes Income Tax Expense (Benefit) Payments on revenue interest liability Revenue Interests payments Payments From Revenue Interest Purchase Agreement The cash outflow from a revenue interest purchase agreement. Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Percentage of cumulative purchaser payments Percentage Of Cumulative Purchaser Payments, Guarantee Percentage Of Cumulative Purchaser Payments, Guarantee Weighted-average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Percentage of royalties to be received on the net sales Percentage of Royalties to be Received on Net Sales The percentage of royalties to be received on net sales. Loss Contingencies [Line Items] Loss Contingencies [Line Items] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] License and Collaboration Agreement Collaborative Arrangement [Member] Investments Debt Securities, Available-for-Sale [Line Items] Debt issuance costs Debt Issuance Costs, Gross Common stock, $0.001 par value; 240,000,000 shares authorized as of March 31, 2023 and as of December 31, 2022; 89,237,167 shares issued at March 31, 2023 and 76,564,396 shares issued at December 31, 2022 Common Stock, Value, Issued Warrants exercised (in shares) Class of Warrant or Right, Exercised Class of Warrant or Right, Exercised Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Exchange Agreement, weighted average price per share floor (in dollars per share) Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor Vesting of restricted stock units and performance-based restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Convertible Debt Convertible Debt [Member] Type Of Risk [Domain] Type Of Risk [Domain] Type Of Event [Domain] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Relative Risk Relative Risk [Member] Relative Risk Debt instrument, required amount outstanding Debt Instrument, Covenant, Required Amount Outstanding Debt Instrument, Covenant, Required Amount Outstanding Fair value of warrants Adjustments to Additional Paid in Capital, Warrant Issued Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue from collaborations Contract with Customer, Liability, Current Cash Equivalents Cash Equivalents [Member] Schedule of Company's Cash Equivalents and Short-Term Investments Unrealized Gain (Loss) on Investments [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Convertible notes, net of issuance costs Convertible Notes Payable, Noncurrent Fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Royalty revenue and product sales bulk tablets Royalty Revenue And Product Sales Bulk Tablets [Member] Royalty Revenue And Product Sales Bulk Tablets Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Debt instrument, face amount Debt Instrument, Face Amount Vesting of ESPP Shares Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Effective annual imputed interest rate (as a percent) Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement. Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Additional cash payment to the Company upon grant of marketing authorization Additional Cash Payment To Be Received Upon Grant Of Marketing Authorization Additional cash payment to the Company upon grant of marketing authorization dependent on the range of relative risk reduction in the CLEAR outcomes study. Entity Current Reporting Status Entity Current Reporting Status Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Revenue Interest Purchase Agreement (RIPA) Revenue Interest Purchase Agreement [Member] Represents the information pertaining to revenue interest purchase agreement ("RIPA"). Liability From Sale Of Future Revenues [Roll Forward] Liability From Sale Of Future Revenues [Roll Forward] Liability From Sale Of Future Revenues Vesting of ESPP Shares (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Additional consideration (in dollars per share) Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights Outstanding at the beginning of period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Estimated offering expenses Payments for Commissions Intangible assets Intangible Assets, Net (Including Goodwill) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code The Company and Basis of Presentation Collaborations with Third Parties Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Stock options Common shares under option Share-Based Payment Arrangement, Option [Member] Treasury stock, at cost; 1,994,198 shares at March 31, 2023 and December 31, 2022 Treasury Stock, Value Additional consideration per amended warrant (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Long-Term Debt Other income, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, authorized (in shares) Common Stock, Shares Authorized The Warrants The Warrants [Member] The Warrants Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Common stock Common Class A [Member] PBSOs Common shares under PBSOs Share Based Payment Arrangement, Option, Performance Based [Member] Share Based Payment Arrangement, Option, Performance Based Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Proceeds from Revenue Interest Purchase Agreement Proceeds from Revenue Interest Purchase Agreement Proceeds from Revenue Interest Purchase Agreement Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Entity Small Business Entity Small Business Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Accrued variable consideration Accrued Variable Consideration, Current Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees Revenues: Revenues [Abstract] Specified net revenue Specified Net Revenue Threshold Triggering Deposit In Blocked Account Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account Restricted cash Restricted Cash Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Class of warrant or right, premium percentage Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Initial revenue interest rate Revenue Interest Rate, Initial Rate The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory. Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Common Stock And Accompanying Warrant Common Stock And Accompanying Warrant [Member] Common Stock And Accompanying Warrant Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Short-term investments Short-Term Investments Payables and Accruals [Abstract] Payables and Accruals [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Amortization of premiums and discounts on investments Amortization of premiums and discounts on investments Accretion (Amortization) of Discounts and Premiums, Investments Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Stock Option And Incentive Plan 2022 Stock Option And Incentive Plan 2022 [Member] Stock Option And Incentive Plan 2022 Accrued clinical development costs Accrued Clinical Development Costs, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer). Non cash right of use asset Non Cash Right Of Use Asset Represents the difference between the lease asset and the lease liability. Liability Related to the Revenue Interest Purchase Agreement Liability Related to the Revenue Interest Purchase Agreement No definition. Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Gross proceeds Sale of Stock, Consideration Received on Transaction Inventories, net Total Inventory Inventory, Net Accounts payable Accounts Payable, Current Net Sales Less Than $250 Million Net Sales Threshold One [Member] Net Sales Threshold One Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate. Warrants Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Deferred up-front payment Deferred Up-Front Payment Deferred Up-Front Payment Stock-based compensation expense Share-Based Payment Arrangement, Expense Common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid Common Stock Issuance Costs Incurred, Not Yet Paid Common Stock Issuance Costs Incurred, Not Yet Paid U.S. treasury notes US Treasury Notes Securities [Member] Commitments and contingencies (Note 5) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding at the beginning of period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Company deposit value in blocked account Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Loss on modification of debt Gains (Losses) on Restructuring of Debt Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Partner milestone payments Potential Proceeds From Partner Milestone Payments Potential Proceeds From Partner Milestone Payments Gross proceeds from revenue interest liability Gross Proceeds from Revenue Interest Purchase Agreement The cash inflow from a revenue interest purchase agreement. Total Revenues Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label Future Payment Milestone, Achievement of Drug Trial Outcomes Studies The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Liability Related to the Revenue Interest Purchase Agreement Liability Related to The Revenue Interest Purchase Agreement [Text Block] The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland"). Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Stock Compensation Share-Based Payment Arrangement [Text Block] Work in process Inventory, Work in Process, Net of Reserves RIPA Amendment Revenue Interest Purchase Agreement Amendment [Member] Revenue Interest Purchase Agreement Amendment Period Two Debt Instrument, Redemption, Period Two [Member] Purchase price (in dollars per share) Class of Warrant or Right, Purchase Price Of Warrants Or Rights Class of Warrant or Right, Purchase Price Of Warrants Or Rights Total liabilities and stockholders’ deficit Liabilities and Equity Maximum annual contributions per employee, as a percentage of base salary Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Redemption percentage Revenue Interest Payments, Redemption Percentage Revenue Interest Payments, Redemption Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Shares delivered to the company (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Level 2 Fair Value, Inputs, Level 2 [Member] Period One Debt Instrument, Redemption, Period One [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Repayment amount expected to pay in next twelve months Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Payment of issuance costs Payment of issuance costs Payments of Stock Issuance Costs Amount of subsequent installment, subject to achievement of sales threshold Amount of Subsequent Installment, Subject to Achievement of Sales Threshold The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Customer Concentration Risk Customer Concentration Risk [Member] Unvested RSUs Unvested Restricted Stock And Restricted Stock Units [Member] Represents information pertaining to unvested restricted stock and restricted stock units. Provision for income taxes Income Tax Expense (Benefit), Continuing Operations [Abstract] Hypothetical sales generated amount Hypothetical Sales Generated Amount Hypothetical Sales Generated Amount Wainwright Wainwright [Member] Wainwright Entity Address, Address Line One Entity Address, Address Line One Stock-based compensation capitalized into inventory Share-Based Payment Arrangement, Amount Capitalized Capped Call Capped Call [Member] Capped Call Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Interest expense Interest expense Interest Expense Amount of maximum annual contributions per employee Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount Maximum amount the employee may contribute to an employee stock purchase plan. Proceeds from sales/maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Cash payment to be received upon certain commercial milestones Cash Payment To Be Received Upon Certain Commercial Milestones Cash Payment To Be Received Upon Certain Commercial Milestones Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Inventories, net Inventory Disclosure [Text Block] Equity [Abstract] Percentage of revenue interests payment on which agreement terminates Percentage Of Revenue Interests Payment on Which Agreement Terminates Percentage of revenue interests payment on which agreement terminates. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Number of commons stock shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Oberland Eiger Iii Sa Llc [Member] Represents the information pertaining to revenue interest purchase agreement ("RIPA") with Oberland. Research and development Research and Development Expense (Excluding Acquired in Process Cost) Nature of Expense [Axis] Nature of Expense [Axis] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued interest receivable Accrued Investment Income Receivable Summary of Significant Accounting Policies Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Statements of Cash Flows and Restricted Cash Cash and Cash Equivalents Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Interest income on investments Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted-Average Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaborations with Third Parties Collaborative Arrangement Disclosure [Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accrued other Other Accrued Liabilities, Current Aggregate offering price shares Sale Of Stock, Authorized Amount Sale Of Stock, Authorized Amount City Area Code City Area Code Accrued professional fees Accrued Professional Fees, Current Assets Assets [Abstract] At The Market Program At The Market Program [Member] At The Market Program Non-cash interest expense related to the revenue interest liability Non Cash Interest Expense Related to Revenue Interest Liability The amount of non-cash expense included in interest expense associated with the revenue interest liability. Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Total shares of common stock from exercisable warrants outstanding (in shares) Class of Warrant or Right, Outstanding Net Sales Threshold [Domain] Net Sales Threshold [Domain] Net Sales Threshold Net Sales Greater Than $250 Million But Less Than $350 Million Net Sales Threshold Two [Member] Net Sales Threshold Two Cardiovascular Risk Cardiovascular Risk [Member] Cardiovascular Risk Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021 Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021. Warrant Amendment Agreements Warrant Amendment Agreements [Member] Warrant Amendment Agreements The Company and Basis of Presentation Business Description and Basis of Presentation [Text Block]